Why Recursion Pharmaceuticals Stock Tanked on Tuesday

Key Points

• Investors sold out of the biotech following a quarterly earnings release this morning.

• The company posted a deeper-than-expected net loss.

• 10 stocks we like better than Recursion Pharmaceuticals ›

Before market open on Tuesday, Recursion Pharmaceuticals (NASDAQ: RXRX) published its latest set of quarterly earnings and business update. It might have wished it hadn't, as those quarterly numbers clearly didn't impress the market. The company's stock ended up closing the day almost 5% lower in price, a steeper fall than the 0.5% dip of the benchmark S&P 500 index.

Second quarter: revenue rose, but net loss deepened

For its second quarter, Recursion earned $19.2 million in revenue, which was up from the slightly more than $14.4 million in the same period of 2024. However, the clinical-stage biotech company's generally accepted accounting principles (GAAP) net loss deepened considerably, coming in at almost $172 million ($0.41) against the $97.5 million deficit in the year-ago period.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Image source: Getty Images.

Although analysts tracking the stock were collectively modeling a lower revenue figure of $15.4 million, their net loss estimate was considerably narrower, at $0.35 per share.

Recursion, which targets cancer and rare disorders with its investigational drugs, provided an update on its pipeline. The most advanced of its programs, oncology drug REC-617, advanced into a phase 1/2 clinical trial in the first half of the year.

Teaming up

As a biotech without a product currently on pharmacy shelves, Recursion generates modest revenue largely from collaborations with large pharmaceutical companies. Among these well-known mainstays are Bayer and Merck.

In the earnings release, it updated the status of several of these; an especially promising one now is a tie-up with Sanofi, which has the potential to produce more than $300 million in milestone payments.

Should you invest $1,000 in Recursion Pharmaceuticals right now?

Before you buy stock in Recursion Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,103,313!*

Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of August 4, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy.